Computed Tomography-Guided Percutaneous Radiofrequency Ablation in Older Adults With Early-Stage Peripheral Lung Cancer: A Retrospective Cohort Study
Overview
Affiliations
Objectives: To evaluate the feasibility, safety, and efficacy of computed tomography(CT)-guided percutaneous radiofrequency ablation (RFA) in medically inoperable older adults with clinical stage I non-small cell lung cancer (NSCLC).
Patients And Methods: We retrospectively reviewed the records of medically inoperable older adults (≥70 years) with clinical stage I NSCLC who underwent percutaneous multi-tined electrode RFA at our institution between January 2014 and December 2018. We analyzed the patients' characteristics, therapy response, survival, as well as the procedure-related complications.
Results: Eighteen patients (10 men and 8 women) with a mean age of 75.9 (71-85) years were treated in during the study period. The median tumor size was 25 mm (range, 19-43 mm); 10 and 8 cases involved stage T1 and T2a disease, respectively. The median follow-up duration was 25 (11-45) months. RFA was technically successful for all 18 lesions, with no treatment-related mortality. The disease control rate was 83.3% (15/18 lesions). There were 6 cases of pneumothorax: one symptomatic case requiring thoracic drainage, and five requiring no treatment. Minor complications, including pulmonary infection, chest pain, fever, and cough, were treated within 4 days (range, 1-4 days). The progression-free survival rates were 83.3%, 64.9%, and 51.9% 1, 2, and 3 years, respectively. The corresponding overall survival rates were 92.2%, 81.5%, and 54.3%, respectively.
Conclusions: CT-guided percutaneous RFA is safe and effective in medically inoperable patients with stage I NSCLC and could be an alternative therapeutic strategy, particularly in older adults with early-stage peripheral lung cancer.
Wang N, Xue T, Zheng W, Shao Z, Liu Z, Dai F Thorac Cancer. 2024; 15(28):1989-1999.
PMID: 39155057 PMC: 11444927. DOI: 10.1111/1759-7714.15425.
Hung W, Tsai S, Wu T, Tu H, Lin H, Su C Thorac Cancer. 2024; 15(11):867-877.
PMID: 38419563 PMC: 11016418. DOI: 10.1111/1759-7714.15255.
Zhao Q, Wang J, Fu Y, Hu B Thorac Cancer. 2023; 14(32):3181-3190.
PMID: 37740563 PMC: 10643797. DOI: 10.1111/1759-7714.15114.
Quang T, Yang J, Mikhail A, Wood B, Ramanujam N, Mueller J JCO Glob Oncol. 2023; 9:e2300155.
PMID: 37625104 PMC: 10581629. DOI: 10.1200/GO.23.00155.
Zhang X, Meng L, Xiao Y, Chen Z Front Oncol. 2022; 12:1059308.
PMID: 36465403 PMC: 9716141. DOI: 10.3389/fonc.2022.1059308.